Featured Research

from universities, journals, and other organizations

Immunotherapy for prostate cancer in sight

Date:
May 26, 2014
Source:
Medical University of Vienna
Summary:
Patients with advanced prostate cancer have now been given some hope from a new study. In just a few years’ time, Ipilumumab could be approved as a treatment for the world’s third-most common type of cancer, researchers predict. Worldwide, prostate cancer is the third-most common form of cancer and is globally the sixth-most common cause of death from cancer among men.

An international study carried out with involvement of the MedUni Vienna is giving hope to patients with advanced prostate cancer. In just a few years' time, Ipilumumab could be approved as a treatment for the world's third-most common type of cancer.

Related Articles


The immunotherapeutic agent Ipilumumab has been shown to have a markedly positive effect in the treatment of patients who are resistant to conventional hormone treatments and chemotherapy. These are the words of a core statement from a study, recently published in the journal The Lancet Oncology, which was set up based on collaboration between the world's leading centres for the research and treatment of prostate cancer.

The scientists investigated the extent to which immunotherapy with this agent is also suitable for the more common type of advanced prostate cancer. The medication is already being successfully used as immunotherapy for advanced melanoma -- a comparatively rare type of cancer.

Major success in the immunotherapy of carcinomas

Michael Krainer, Head of the Urological Tumours Working Group within the Department of Oncology (University Department of Internal Medicine I) at the MedUni Vienna, which played a key role as the lead recruitment centre for Germany and Austria, had this to say about the study results: "For us, it is virtually a miracle that immunotherapy demonstrates such a clear effect at such a late stage of the disease. The results of our study must be regarded as a further major success in the immunotherapy of carcinomas." The substance's mechanism of action is as follows: the Ipilumumab antibodies disable "inhibitors," giving the body's immune system a boost.

Approval of the medication in sight

Despite this good effect, it's not all plain sailing: the "revved up" immune system can also attack the body's own tissues. According to the study, Ipilumumab is therefore not suitable -- in view of its side effects -- for treating patients with advanced prostate cancer who are in poor general health. For this reason, a further study is currently underway and is expected to be completed in 2015. This follow-on study is limited to patients with a better prognosis and who are in better overall health. Krainer expresses his expectations thus: "Based on our results, I anticipate that this study will bring approval for Ipilumumab for patients with advanced prostate cancer."

European Centre of Expertise for urological tumours

The Urological Tumours Working Group at the MedUni Vienna is regarded across Europe as one of the most highly respected study support centres in the field of prostate cancer. Since 2002, several hundred patients have been included in 17 clinical studies. The spectrum covers all modern treatment options and ranges from chemotherapy and hormone therapy to immunotherapy.

Prostate cancer: the third-most common form of cancer

Worldwide, prostate cancer is the third-most common form of cancer and is globally the sixth-most common cause of death from cancer among men. Each year, around 300,000 men are diagnosed with the condition within the European Union, and around two million men in the EU are currently living with the condition.


Story Source:

The above story is based on materials provided by Medical University of Vienna. Note: Materials may be edited for content and length.


Journal Reference:

  1. Eugene D Kwon, Charles G Drake, Howard I Scher, Karim Fizazi, Alberto Bossi, Alfons J M van den Eertwegh, Michael Krainer, Nadine Houede, Ricardo Santos, Hakim Mahammedi, Siobhan Ng, Michele Maio, Fabio A Franke, Santhanam Sundar, Neeraj Agarwal, Andries M Bergman, Tudor E Ciuleanu, Ernesto Korbenfeld, Lisa Sengelψv, Steinbjorn Hansen, Christopher Logothetis, Tomasz M Beer, M Brent McHenry, Paul Gagnier, David Liu, Winald R Gerritsen. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. The Lancet Oncology, 2014; 15 (7): 700 DOI: 10.1016/S1470-2045(14)70189-5

Cite This Page:

Medical University of Vienna. "Immunotherapy for prostate cancer in sight." ScienceDaily. ScienceDaily, 26 May 2014. <www.sciencedaily.com/releases/2014/05/140526101656.htm>.
Medical University of Vienna. (2014, May 26). Immunotherapy for prostate cancer in sight. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2014/05/140526101656.htm
Medical University of Vienna. "Immunotherapy for prostate cancer in sight." ScienceDaily. www.sciencedaily.com/releases/2014/05/140526101656.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) — An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins